How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

381. Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

glucocorticoid therapy for >2 weeks within the 4 weeks immediately preceding screening. Have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of screening. Have previously been treated with glucagon-like peptide 1 analogs or liraglutide. Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior

2008 Clinical Trials

382. Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

contraceptives. Treatment with cyclosporine except for ophthalmic indication Anti-obesity medications such as orlistat or sibutramine taken within 3 months prior to Visit 1. Therapeutic doses of systemic corticosteroids except inhaled steroid therapy (for example, Pulmicort®) maintained on a stable dosing regimen for at least 6 weeks prior to randomization (Visit 3) and throughout the duration of the study Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2008 Clinical Trials

383. Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment

be included in the trial. The dose should have remained unchanged for a period of 2 months prior to randomisation and should be expected to remain unchanged throughout the trial period) Use of approved weight lowering pharmacotherapy (e.g. orlistat, sibutramin, rimonabant) or obesity induced by drug treatment (e.g. corticosteroids, Non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic anti-depressants, atypical anti-psychotics) Previous or planned surgical treatment of obesity Total daily insulin dose

2008 Clinical Trials

384. Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics. Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1. Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening. Have a history of renal transplantation or are currently receiving renal dialysis. Have

2008 Clinical Trials

385. Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

/products that is intended to induce weight loss, appetite suppression, weight control or treat obesity, including, but not limited to, phentermine, sibutramine, orlistat, ephedra, rimonabant and other anorexogenics and/or stimulants, as well as topiramate, etc. Note: Use of any other medications/products for weight control, appetite suppression, treatment of obesity is prohibited during the course of this OLE study Current or planned use of chronic medications/products that are known to cause weight

2008 Clinical Trials

386. Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

episodes during their lifetime or >1 episode within the past year resulting in hypoglycemic seizures, comas, or unconsciousness is on a weight loss program and is not in the maintenance phase, or patient is taking a weight loss medication (e.g., orlistat, sibutramine, rimonabant) within 8 weeks of Visit 1 has undergone surgery within 30 days prior to Visit 1 or has planned major surgery Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2008 Clinical Trials

387. LOSS- Louisiana Obese Subjects Study

is compared to a usual care treatment model where individuals utilize self directed approaches to weight loss. The active treatment period is three years, followed by two years of observation. Condition or disease Intervention/treatment Phase Obesity Behavioral: group sessions Drug: sibutramine, orlistat, diethylpropion Behavioral: Low Calorie Diet, Health One Other: Intensive Medical Combination Therapy for Obesity Other: Control Condition Phase 4 Study Design Go to Layout table for study information (...) Diet, Weight loss medications, Group Behavioral Therapy and a "Tool Box" approach Behavioral: group sessions group sessions lead by a trained primary care clinic employee Drug: sibutramine, orlistat, diethylpropion dosage modified according to package insert instructions at discretion of primary care physicians Behavioral: Low Calorie Diet, Health One liquid diet for 8-12 weeks to induce weight loss Other: Intensive Medical Combination Therapy for Obesity Very Low Calorie Liquid diet, Group

2005 Clinical Trials

388. The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose

6 weeks before randomisation : lipid lowering drug other than study medication, Cyclosporine A, medical treatment against obesity (i.e., Orlistat, Sibutramine), oral anticoagulants. Special attention will be paid to the medications that could interfere with the lipid profile (i.e. oral corticosteroids, retinoids, thyroid hormones, thiazide derivative, diuretics, beta-blockers, and hormone replacement therapies). It is recommended not to modify these medications within 6 weeks prior to study

2005 Clinical Trials

389. A Comparative Study of KES524 in Patients With Obesity Disease

scan, HbA1c, TG and HDL-C (secondary endpoints). Condition or disease Intervention/treatment Phase Obesity Drug: Sibutramine Hydrochloride Monohydrate Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: A Double-Blind, Placebo-Controlled, Comparative Study of KES524 in Patients With Obesity Disease Study Start Date : July (...) Clinical Research Dept., Clinical Research Center More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: KES524-J081-161 First Posted: September 14, 2005 Last Update Posted: January 29, 2010 Last Verified: January 2010 Additional relevant MeSH terms: Layout table for MeSH terms Obesity Overnutrition Nutrition Disorders Overweight Body Weight Signs and Symptoms Sibutramine Antidepressive Agents Psychotropic Drugs Appetite Depressants Anti

2005 Clinical Trials

390. Metformin Obesity Study

of insulin or insulin analogs; or any oral antidiabetic medication; acarbose, acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide, metformin, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide or troglitazone. Prior use of drugs to aid in weight loss, including but not limited to: Benzphetamine Hcl, Diethylpropion Hcl, Fenfluramine Hcl, Phendimetrazine Tartrate, Phentermine Hcl, Orlistat, Sibutramine Hcl Monohydrate, Didrex, Tenuate, Pondimin, Bontril-SR, Adipex-P, Fastin

2005 Clinical Trials

391. Dairy Products and Metabolic Effects (Norwegian Part)

with Cyclosporin A. Change within the last 6 weeks before randomisation and during the study in the medications that could interfere with the lipid profile (i.e., anti- hypertensive drugs, oral corticosteroids, thyroid hormones, retinoids, thiazidic derivative, hormone replacement therapy). Treated with oral anticoagulants. Treated with protease inhibitors (indinavir, ritonavir, saquinavir) Treated against obesity: medical treatment within the last 6 weeks (orlistat, sibutramine) and/or surgery (gastroplasty

2005 Clinical Trials

392. A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression Condition or disease Intervention/treatment Phase Obesity Drug: CP-945,598 Drug: sibutramine Phase 2 Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 282 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment Official Title: A 6 (...) Call Center Pfizer More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: A5351013 First Posted: August 24, 2005 Last Update Posted: August 12, 2009 Last Verified: April 2006 Additional relevant MeSH terms: Layout table for MeSH terms Weight Loss Body Weight Changes Body Weight Signs and Symptoms Sibutramine Antidepressive Agents Psychotropic Drugs Appetite Depressants Anti-Obesity Agents

2005 Clinical Trials

393. Treatment Study of Frontotemporal Dementia

a stimulant (methylphenidate, dextroamphetamine, pemoline, or modafinil), or an antipsychotic medication, typical or atypical, including prochlorperazine and metoclopromide. Patients taking any of the following medications because of their potential interaction with dextroamphetamine: MAO use currently or within 14 days prior to start of study, Furazolidone, Guanethidine, norepinephrine, sibutramine, tricyclic antidepressants, carbonic anhydrase inhibitors. Patients taking the following medications

2004 Clinical Trials

394. Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

phase Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) Patient has any of the following

2004 Clinical Trials

395. Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

will be provided in the SPM). Use of non-medication treatments for VMS, such as acupuncture and biofeedback, and other complementary or alternative therapies for VMS relief (with the exception of black cohosh and red clover which require a specified washout previously noted) must be discontinued at Visit 1. iii.Use of weight loss drugs (e.g., phentermine, sibutramine, orlistat, rimonabant) within 3 months of the first dose of investigational product. Other complementary or alternative therapies for weight

2008 Clinical Trials

396. The Effect of Vitamin D Repletion on Insulin Resistance

on more than one screening visit History of kidney stones History of chronic hepatitis, or liver enzymes (AST or ALT) more than 2.5 times the upper limit of normal Primary hyperparathyroidism or baseline hypercalcemia from any cause Current treatment with over-the-counter or prescription weight loss medications, such as orlistat or sibutramine History of bariatric surgery Current treatment with any cholesterol-lowering medications, such as statins, niacin, fibrates, or ezetimibe Blood pressure ≥ 145

2008 Clinical Trials

397. Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward

, Tenuate Dospan®) Methylphenidate (Metadate CD®, Ritalin LA®, Methylin®, Ritalin®, Metadate ER®, Ritalin SR®, Methylin ER®, Daytrana®, Concerta®) Pemoline (Cylert®) Benzphetamine (Didrex®) Phendimetrazine (Adipost®, Bontril®, Melfiat®, Prelu-2®, X-Trozine LA®, Bontril PDM®, Obezine®, Obezine caplets) ® Phentermine (Ionamin®, Phentride®, Teramine®, Adipex-P®) Sibutramine (Meridia®) Caffeine (No Doz®, Quick-Pep®, Vivarin®, Caffedrine®,Caffeine and sodium benzoate inj, Cafcit®) Doxapram (Dopram®

2008 Clinical Trials

398. Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

Used drugs for weight loss (e.g., orlistat, rimonabant, sibutramine, or similar over-the-counter medications) within 3 months prior to screening. Are currently treated with any of the following excluded medications: Sulfonylurea or meglitinide derivatives (e.g., repaglinide or nateglinide) within 3 months prior to screening Alpha-glucosidase inhibitor (e.g., miglitol or acarbose) within 3 months of screening Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin or vildagliptin) within 3

2008 Clinical Trials

399. BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

(serum creatinine >/= 1.5 mg/dl) as determined at Visit 1a Treatment with rosiglitazone or pioglitazone within 3 months prior to the date of informed consent Treatment with GLP-1 analogues (e.g. exenatide) within 3 months prior to the date of informed consent Treatment with insulin within 3 months prior to the date of informed consent Treatment with anti-obesity drugs (e.g. sibutramine, rimonabant, orlistat) within 3 months prior to the date of informed consent Current treatment with systemic

2008 Clinical Trials

400. Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

within 3 months prior to informed consent Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse Participation in another trial with an investigational drug within 2 months prior to informed consent Pre-menopausal women who: are nursing or pregnant, or are of child-bearing potential and are not practicing an acceptable

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>